Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 281
Filtrar
1.
Sci Rep ; 14(1): 20793, 2024 09 05.
Artículo en Inglés | MEDLINE | ID: mdl-39242643

RESUMEN

Intellectual drug doping in athletics by using stimulants that affect central nervous system functions has been diversified. Stimulants are regulated by the World Anti-Doping Agency according to their levels of urinary concentration. Positron emission tomography could evaluate how stimulants affect central nervous system functions. We aimed to evaluate the effect of stimulants on brain function by examining the difference in brain dopamine transporter occupancy by PET after administration of dl-methylephedrine or pseudoephedrine at the clinical maximum daily dose. Four PET scans without and with drug administration (placebo, dl-methylephedrine 150 mg and pseudoephedrine 240 mg) were performed. The concentrations of dl-methylephedrine and pseudoephedrine in plasma and urine were measured. DAT occupancies in the striatum with placebo, dl-methylephedrine and pseudoephedrine were calculated by PET images. The urinary concentration of dl-methylephedrine (12.7 µg/mL) exceeded the prohibited concentration (10 µg/mL), but the DAT occupancy with dl-methylephedrine (6.1%) did not differ (p = 0.92) from that with placebo (6.2%). By contrast, although the urinary concentration of pseudoephedrine (144.8 µg/mL) was below the prohibited concentration (150 µg/mL), DAT occupancy with pseudoephedrine was 18.4%, which was higher than that with placebo (p = 0.009). At the maximum clinical dose, dl-methylephedrine was shown to have weaker effects on brain function than pseudoephedrine.


Asunto(s)
Encéfalo , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática , Tomografía de Emisión de Positrones , Seudoefedrina , Humanos , Masculino , Tomografía de Emisión de Positrones/métodos , Seudoefedrina/farmacología , Seudoefedrina/administración & dosificación , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Encéfalo/diagnóstico por imagen , Adulto , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Adulto Joven , Estimulantes del Sistema Nervioso Central/farmacología , Estimulantes del Sistema Nervioso Central/orina , Estimulantes del Sistema Nervioso Central/administración & dosificación , Doping en los Deportes/prevención & control , Femenino , Efedrina/análogos & derivados
2.
J Anal Toxicol ; 48(5): 254-262, 2024 Jun 11.
Artículo en Inglés | MEDLINE | ID: mdl-38706158

RESUMEN

Illegal amphetamine is usually composed of a racemic mixture of the two enantiomers (S)- and (R)-amphetamine. However, when amphetamine is used in medical treatment, the more potent (S)-amphetamine enantiomer is used. Enantiomer-specific analysis of (S)- and (R)-amphetamine is therefore used to separate legal medical use from illegal recreational use. The aim of the present study was to describe our experience with enantiomer-specific analysis of amphetamine in urine and oral fluid, as well as blood, and examine whether the distribution of the two enantiomers seems to be the same in different matrices. We investigated 1,722 urine samples and 1,977 oral fluid samples from prison inmates, and 652 blood samples from suspected drugged drivers, where prescription of amphetamine was reported. Analyses were performed using ultra high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS-MS). The enantiomer separation was achieved by using a chiral column, and results from the method validation are reported. Samples containing <60% (S)-amphetamine were interpreted as representing illegal use of amphetamine. The distribution of the two enantiomers was compared between different matrices. In urine and oral fluid, the mean amount of (S)-amphetamine was 45.2 and 43.7%, respectively, while in blood, the mean amount of (S)-amphetamine was 45.8%. There was no statistically significant difference in the amount of (S)-amphetamine between urine and oral fluid samples and between urine and blood samples, but the difference was significant in blood compared to oral fluid samples (P < 0.001). Comparison of urine and oral fluid between similar populations indicated that enantiomers of amphetamine can be interpreted in the same way, although marginally higher amounts of (R)-amphetamine may occur in oral fluid. Oral fluid, having several advantages, especially during collection, could be a preferred matrix in testing for illegal amphetamine intake in users of medical amphetamine.


Asunto(s)
Anfetamina , Saliva , Detección de Abuso de Sustancias , Espectrometría de Masas en Tándem , Humanos , Anfetamina/orina , Anfetamina/sangre , Anfetamina/análisis , Saliva/química , Estereoisomerismo , Detección de Abuso de Sustancias/métodos , Cromatografía Líquida de Alta Presión , Estimulantes del Sistema Nervioso Central/orina , Estimulantes del Sistema Nervioso Central/sangre , Estimulantes del Sistema Nervioso Central/análisis
3.
J Anal Toxicol ; 48(6): 447-455, 2024 Jul 13.
Artículo en Inglés | MEDLINE | ID: mdl-38648396

RESUMEN

Drug-impaired driving is an increasing public safety concern across Canada, particularly due to the demonstrated increase in use of recreational drugs such as cocaine. Cocaine is a central nervous system stimulant drug; however, it can impair an individual's driving ability in both the stimulant and crash phases. Despite the scientific consensus regarding cocaine's potential for driving impairment, there is relatively little information available regarding blood concentrations and associated observations of impairment in suspected impaired drivers. Retrospective data analysis was performed to evaluate suspected impaired driving cases in which cocaine and/or benzoylecgonine were detected alone, or in combination with other drugs, in blood and urine samples submitted to the Toxicology Section of the Centre of Forensic Sciences with incident dates between 2021 and 2022. Cocaine and/or benzoylecgonine were detected in 46% (blood) and 66% (urine) of the total impaired driving samples submitted. In 41 cases where cocaine and/or benzoylecgonine were the only drug finding in blood, concentrations of cocaine and benzoylecgonine ranged from 0.0073 to 0.26 mg/L (mean 0.096 mg/L) and 0.13 to 5.3 mg/L (mean 2.1 mg/L), respectively. Driving observations reported by the arresting officer in cases where cocaine and/or benzoylecgonine were the only drug finding in blood and urine included the driver being involved in a collision, the vehicle leaving the roadway, erratic driving and the driver being asleep at the wheel; observations of drug impairment reported by the drug recognition expert at the time of driver evaluation included abnormal speech patterns, poor balance/incoordination, abnormal body movements and the individual falling asleep. The results provide concentrations of cocaine and benzoylecgonine observed in suspected impaired drivers, insight into observations that may be associated with prior cocaine use and additional information to inform on the effects of cocaine on driving.


Asunto(s)
Cocaína , Conducir bajo la Influencia , Detección de Abuso de Sustancias , Cocaína/análogos & derivados , Cocaína/sangre , Humanos , Detección de Abuso de Sustancias/métodos , Ontario/epidemiología , Estudios Retrospectivos , Conducción de Automóvil , Drogas Ilícitas/sangre , Drogas Ilícitas/orina , Trastornos Relacionados con Cocaína/epidemiología , Masculino , Toxicología Forense , Femenino , Adulto , Estimulantes del Sistema Nervioso Central/sangre , Estimulantes del Sistema Nervioso Central/orina
4.
J Pharm Biomed Anal ; 241: 115996, 2024 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-38330785

RESUMEN

BACKGROUND AND AIM: Non-medical use of Pregabalin (PGB) is a growing concern in many countries because of the serious consequences associated with their abuse. Judicial cases within the probation system, multiple drug users, and patients in treatment programs administered PGB at higher doses than suggested, commonly without prescription. For this reason, it is important to analyze PGB by adding it to the routine analysis scale in determining whether PGB is used for medical purposes or abuse. In this study, PGB analyzed (single or multiple substance use, concomitant substances) in urine samples of forensic and clinical cases by liquid chromatography-tandem mass spectrometry (LC-MS/MS). In addition to the sociodemographic and clinical characteristics of pregabalin-positive cases, the results were evaluated separately from a clinical and forensic perspective. METHODS: All urine samples which was admitted to Addiction Toxicology Laboratory from 'drug abuse probation system' (forensic cases, n = 640) and from various departments of our hospital (clinical cases, n = 371) between December 2022 and April 2023. Screening analysis were carried out by immunoassay in total 1011 cases. LC-MS/MS method simultaneously analyzed amphetamine, benzoilecgonine, cocaine, codeine, metamphetamine, morphine, 3,4-metilenedioksi-N-metilamfetamin (MDMA), 11-nor-9-karboksi-Δ9-tetrahidrokannabinol and pregabalin in urine samples. PGB was added to the our routine substance screening analysis scale in December 2022 to detect pregabalin use. RESULTS: PGB was detected in 12.3% of probabition cases and 13.2% of clinical cases. The mean age of PGB positive cases was 26.55 ± 7,52 years old, predominantly males (%85,9). Single PGB was detected in 53.2% of forensic cases (n = 42), and 38.7% of clinical cases (n = 19). The most common substance detected concomitantly with PGB was amphetamine type stimulants (ATSs:amphetamine, methamphetamine, ecstasy/MDMA etc.) (22.8% of forensic cases and 46.9% of clinical cases), followed by concomitant cannabis use (24.1% of forensic cases and 26.5% of clinical cases). Concomitant opioid use was rare (1.3% of forensic cases and 4.1% of clinical cases). Detection of PGB was significantly different across months on which the samples were collected (x2 = 82.8, df=4, p < 0.001). CONCLUSION: Inconsistently with previous studies suggesting opioids as the most prevalant substances concominant with PGB, our results showed that stimulants (especially ATSs) were the most prevelant substances concominant with PGB, followed by cannabis. High proportion of PGB detection in probabition cases, frequently as a single substance abuse takes attention. These results suggest that PGB, may be used to avoid legal consequences. It is important for laboratories to be aware that they need to make changes as addition of newly abused substances in their analysis panels, when necessary, as differences between regions and cultures affect substance use patterns.


Asunto(s)
Estimulantes del Sistema Nervioso Central , Alucinógenos , Metanfetamina , N-Metil-3,4-metilenodioxianfetamina , Trastornos Relacionados con Sustancias , Masculino , Humanos , Femenino , N-Metil-3,4-metilenodioxianfetamina/análisis , Pregabalina , Cromatografía Liquida/métodos , Espectrometría de Masas en Tándem/métodos , Anfetamina/orina , Estimulantes del Sistema Nervioso Central/orina , Alucinógenos/análisis , Trastornos Relacionados con Sustancias/diagnóstico , Trastornos Relacionados con Sustancias/epidemiología , Detección de Abuso de Sustancias/métodos
5.
Drug Test Anal ; 14(4): 741-746, 2022 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-34984836

RESUMEN

Mephedrone is a stimulant drug structurally related to cathinone. At present, there are no data available on the excretion profile of mephedrone and its metabolites in urine after controlled intranasal administration to human volunteers. In this study, six healthy male volunteers nasally insufflated 100 mg of pure mephedrone hydrochloride (Day 1). Urine was collected at different timepoints on Day 1 and then on Days 2, 3 and 30. Samples were analysed for the presence of mephedrone and its metabolites, namely, dihydro-mephedrone, nor-mephedrone (NOR), hydroxytolyl-mephedrone, 4-carboxy-mephedrone (4-carboxy) and dihydro-nor-mephedrone (DHNM), by a validated liquid chromatography-tandem mass spectrometry method. All analytes were detected in urine, where 4-carboxy (Cmax = 29.8 µg/ml) was the most abundant metabolite followed by NOR (Cmax = 377 ng/ml). DHNM was found at the lowest concentrations (Cmax = 93.1 ng/ml). Analytes exhibited a wide range of detection windows, but only 4-carboxy and DHNM were detectable in all samples on Day 3, extending the detection time of mephedrone use. Moreover, mephedrone had a mean renal clearance of 108 ± 140 ml/min, and 1.3 ± 1.7% of unchanged parent drug was recovered in urine in the first 6 h post administration. It is hoped that this novel information will be useful in future studies involving mephedrone and other stimulant drugs.


Asunto(s)
Estimulantes del Sistema Nervioso Central , Metanfetamina , Administración Intranasal , Estimulantes del Sistema Nervioso Central/orina , Voluntarios Sanos , Humanos , Masculino , Metanfetamina/análogos & derivados , Espectrometría de Masas en Tándem/métodos
6.
PLoS One ; 16(3): e0248747, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33784320

RESUMEN

Considering the high clinical and forensic relevance of pharmaco-adherence during lisdexamphetamine (LDX) treatment for attention-deficit/hyperactivity disorder (ADHD), the aim here was to evaluate hair analysis as a tool for monitoring compliance in patients currently undergoing long term treatment with LDX, by detecting possible interruptions of medication intake or changes in dosage. For this purpose, a total of 24 patients from an outpatient clinic for ADHD were recruited. Hair and urine samples were taken after three consecutive therapy sessions over a 7-month period and analyzed for amphetamine (AMP) enantiomers and other drugs, using chiral and achiral liquid chromatography-tandem mass spectrometry (LC-MS/MS). Participants also provided information on the condition of their hair, the consumption of illegal psychotropic substances and the regularity of taking LDX. Two participants withdrew from the study early. Urine analyses were positive for D-AMP in all urine samples and therapy sessions, except in two patients who did not take LDX on a daily basis. D-AMP was detected in all hair samples; however, no correlation was found between prescribed dose/day and D-AMP concentrations in proximal hair segments. Qualitative interpretation of hair analysis showed that 18 of the 22 study completers were compliant concerning the intake of LDX without additional consumption of illegal D,L-AMP. Analysis of urine taken during the therapy sessions showed no correlation between D-AMP concentrations and prescribed dosage, with or without normalization for creatinine. In conclusion, chiral LC-MS/MS hair analysis might represent a non-invasive way to confirm LDX use within the approximate period covered by the hair segment tested, but it does not allow for quantitative therapeutic drug monitoring because of interindividual variability of concentrations in hair. Drug concentrations in hair at different stages of long-term treatment should thus be interpreted with caution by clinicians and forensic experts alike when making assessments of treatment adherence.


Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad/tratamiento farmacológico , Estimulantes del Sistema Nervioso Central/administración & dosificación , Monitoreo de Drogas/métodos , Análisis de Cabello/métodos , Cabello/química , Dimesilato de Lisdexanfetamina/administración & dosificación , Cumplimiento de la Medicación , Adulto , Atención Ambulatoria/métodos , Trastorno por Déficit de Atención con Hiperactividad/orina , Estimulantes del Sistema Nervioso Central/orina , Cromatografía Liquida/métodos , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Dimesilato de Lisdexanfetamina/orina , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Espectrometría de Masas en Tándem/métodos , Resultado del Tratamiento , Adulto Joven
7.
Anal Bioanal Chem ; 413(8): 2147-2161, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-33517480

RESUMEN

Resolution of cathinone enantiomers in equine anti-doping analysis is becoming more important to distinguish the inadvertent ingestion of plant-based products from those of deliberate administration of designer synthetic analogs. With this in mind, a rapid and sensitive method was developed and validated for the detection, resolution and quantitative determination of cathinone enantiomers in horse blood plasma and urine. The analytes were recovered from the blood plasma and urine matrices by using a liquid-liquid extraction after adjusting the pH to 9. The recovered analytes were derivatized with Nα-(2,4-dinitro-5-fluorophenyl)-L-valinamide, a chiral derivatizing agent analogous to Marfey's reagent. The resulting diastereoisomers were baseline resolved under a reversed-phase liquid chromatographic condition. Derivatization of the analytes not only allowed the separation of the enantiomers using cost-effective traditional liquid chromatography conditions and reversed-phase columns but also increased the sensitivity, at least to an order of magnitude, when tandem mass spectrometry is used for the detection. A limit of detection of 0.05 ng/mL was achieved for cathinone enantiomers for both matrices. Acceptable intraday and interday precision and accuracy along with satisfactory dilution accuracy and precision were observed during the method validation. The method suitability was tested using the post administration urine samples collected after single doses of cathinone and ephedrine as single-enantiomeric form and methcathinone as racemic form. Finally, a proof of concept of the isomeric ratio in urine samples to distinguish the presence of cathinone as a result of accidental ingestion of plant-based product from that of an illicit use of a designer product is demonstrated. To the best of our knowledge, this is the first such work where cathinone enantiomers were resolved and quantified in horse blood plasma and urine at sub nanogram levels.


Asunto(s)
Alcaloides/sangre , Alcaloides/orina , Estimulantes del Sistema Nervioso Central/sangre , Estimulantes del Sistema Nervioso Central/orina , Caballos/sangre , Caballos/orina , Alcaloides/análisis , Animales , Estimulantes del Sistema Nervioso Central/análisis , Cromatografía Líquida de Alta Presión/métodos , Doping en los Deportes , Límite de Detección , Estereoisomerismo , Detección de Abuso de Sustancias/métodos , Espectrometría de Masas en Tándem/métodos
8.
Am J Emerg Med ; 39: 257.e1-257.e2, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-32674922

RESUMEN

This is a case report of a 19-month-old female who presented to the emergency department in cardiac arrest after methamphetamine exposure. Prior to presentation, she had seizure-like activity and then became unresponsive. On arrival, she had dilated pupils, intermittent clonus, and pulseless electrical activity. She was found to have full thickness circumferential burns of her bilateral lower extremities. She received 12 doses of epinephrine, cardiopulmonary resuscitation, and volume resuscitation after which she had return of spontaneous circulation and was transferred to the intensive care unit on an epinephrine drip. Initial laboratory studies showed a mixed metabolic and respiratory acidosis and hyperglycemia. An initial urine immunoassay for drugs of abuse was negative, however, 5 h later, a second urine immunoassay was positive for amphetamine. The first specimen was also sent for liquid chromatography-mass spectrometry analysis that later returned positive for methamphetamine and amphetamine. In retrospect, the initial urine screen was found to have evidence of amphetamine below the threshold for positivity (500 ng/mL), and the second urine specimen was highly positive, with an amphetamine level of >1450 ng/mL. In this case, what turned out to be a sub-threshold rather than undetectable level was clinically significant, highlighting the challenges of urine screening in cases of suspected poisoning syndromes with atypical presentations. Our case also suggests the possibility of PEA as a presentation of methamphetamine toxicity in a child.


Asunto(s)
Estimulantes del Sistema Nervioso Central/envenenamiento , Paro Cardíaco/inducido químicamente , Metanfetamina/envenenamiento , Intoxicación/diagnóstico , Estimulantes del Sistema Nervioso Central/orina , Femenino , Paro Cardíaco/fisiopatología , Humanos , Lactante , Metanfetamina/orina , Intoxicación/etiología , Intoxicación/orina
9.
Drug Test Anal ; 13(1): 91-100, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-32678963

RESUMEN

We have considered the urinary excretion profile of methiopropamine (MPA), a thiophene ring-based structural analog of methamphetamine with similar stimulant effects, with the aim of selecting the most appropriate marker(s) of intake that may be useful in forensic analysis. For this purpose, in vitro studies were preliminarily performed on human liver microsomes for tracing the phase I metabolic pathways of MPA, preselecting the best candidates as potential target analytes, and designing the optimal experimental strategy. In vivo studies were then conducted on mice, after the intraperitoneal administration of a 10-mg/kg dose. Urine samples were collected every 3 h in the first 9 h and, subsequently, from 24 to 36 h, and stored at -80°C until further analysis. The measurements were performed using a targeted procedure based on liquid/liquid extraction followed by liquid chromatography-tandem mass spectrometry analysis. Our results show that in the time interval 0-9 h after administration, MPA was extensively oxidized mainly to nor-MPA, oxo-MPA, and two hydroxylated metabolites (ie, hydroxy-aryl-methiopropamine and hydroxy-alkyl-methiopropamine). All phase I metabolites underwent phase II metabolism, with the formation of nor-hydroxy-methiopropamine only in phase II, confirmed by the results obtained after enzymatic hydrolysis with ß-glucuronidase and arylsulfatase. In the time interval 24-36 h after administration, only unchanged MPA and nor-MPA were detected, suggesting that these two markers are those endowed with the highest diagnostic value. The method was validated for these two principal markers, proving to be fit for anti-doping, toxicological, and forensic analyses.


Asunto(s)
Metanfetamina/análogos & derivados , Tiofenos/orina , Animales , Estimulantes del Sistema Nervioso Central/administración & dosificación , Estimulantes del Sistema Nervioso Central/orina , Cromatografía Liquida , Drogas de Diseño/administración & dosificación , Drogas de Diseño/análisis , Drogas Ilícitas/orina , Infusiones Parenterales , Masculino , Metanfetamina/administración & dosificación , Metanfetamina/orina , Ratones , Ratones Endogámicos ICR , Detección de Abuso de Sustancias , Espectrometría de Masas en Tándem , Tiofenos/administración & dosificación
10.
Drug Test Anal ; 13(1): 44-68, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-33283466

RESUMEN

Understanding the stability of analyzed drugs in biological samples is a crucial part for an appropriate interpretation of the analytical findings. Synthetic cathinones, as psychoactive stimulants, belong to a major class of new psychoactive substances. As they are subject to several degradation pathways, they are known to clinical and forensic toxicologists as unstable analytes in biological samples. When interpreting analytical data of synthetic cathinones in biological samples, analysts must be aware that the concentration of analytes may not accurately reflect the levels at the time they were acquired owing to many factors. This review provides (i) an overview of the current scientific knowledge on the stability of synthetic cathinones and/or metabolites in various human biological samples with a focus on factors that may deteriorate their stability-such as storage temperature, length of storage, matrix, pH, type of preservatives, concentration of analytes, and the chemistry of the analytes-and (ii) possible solutions on how to avoid such degradation. The PubMed database as well as Google Scholar was thoroughly searched to find published studies on the stability of synthetic cathinones since 2007 by searching specific keywords. A total of 23 articles met the inclusion criteria and were included in this review. Synthetic cathinones that carry methylenedioxy or N-pyrrolidine ring showed higher degradation resistance over other substituted groups. Acidification of samples pH plays a crucial role at increasing the stability of cathinones even with analytes that were frequently considered as poorly stable. This review also provides several recommendations for best practice in planning the experimental design, preservation, and storage conditions in order to minimize synthetic cathinones' degradation in human biological samples.


Asunto(s)
Alcaloides/análisis , Estimulantes del Sistema Nervioso Central/análisis , Estabilidad de Medicamentos , Psicotrópicos/análisis , Alcaloides/sangre , Alcaloides/metabolismo , Alcaloides/orina , Animales , Estimulantes del Sistema Nervioso Central/sangre , Estimulantes del Sistema Nervioso Central/metabolismo , Estimulantes del Sistema Nervioso Central/orina , Monitoreo de Drogas , Almacenaje de Medicamentos , Toxicología Forense , Humanos , Psicotrópicos/sangre , Psicotrópicos/metabolismo , Psicotrópicos/orina , Detección de Abuso de Sustancias
11.
Anal Bioanal Chem ; 412(28): 7837-7850, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-32954468

RESUMEN

A gas chromatography-atmospheric pressure photoionization-high-resolution mass spectrometry (GC-APPI-HRMS) method was developed for the determination of eight phenylalkylamine stimulants in urine samples. Spiked urine samples were hydrolyzed, processed by solid-phase extraction, and derivatized before analysis. Two derivatization reactions were studied: the formation of trimethylsilyl (TMS) derivatives with N-methyl-N-trimethylsilyl trifluoroacetamide (MSTFA) and trimethylsilyl/trifluoroacetyl (TMS/TFA) derivatives with MSTFA and N-methyl-bis (trifluoroacetamide) (MBTFA) as derivatization reagents. Gas chromatography of both derivatives was performed with a 100% dimethylsiloxane column and a good separation of all isomeric compounds was achieved. To maximize the signal of the protonated molecule [M+H]+, the APPI most critical parameters were optimized. Three solvents were tested as dopant agents, with acetone yielding the lower in-source collision-induced dissociation (CID) fragmentation. The acquisition was performed in full scan and product ion scan (parallel reaction monitoring, PRM) using a quadrupole-Orbitrap mass analyzer (35,000 FWHM at m/z 200) in positive ion detection mode. At the optimal working conditions, the full scan method was evaluated for the fulfillment of identification requirements in doping analysis. Selectivity, limits of detection, matrix effect, and precision were estimated to validate the method for confirmation purposes and its applicability was tested by the analysis of spiked samples as well as by the analysis of samples obtained after the administration of some of the compounds to healthy volunteers. Results were compared with those obtained by GC-electron ionization-MS, demonstrating that the GC-APPI-HRMS method improved selectivity and sensibility, achieving lower limits of detection and satisfactory reproducibility.


Asunto(s)
Estimulantes del Sistema Nervioso Central/orina , Cromatografía de Gases y Espectrometría de Masas/métodos , Presión Atmosférica , Doping en los Deportes , Femenino , Humanos , Hidroxilación , Límite de Detección , Masculino , Estándares de Referencia , Reproducibilidad de los Resultados , Detección de Abuso de Sustancias/métodos
12.
Ann Emerg Med ; 76(6): 782-787, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-32782084

RESUMEN

STUDY OBJECTIVE: Concurrent use of amphetamine-type stimulants among individuals with opioid use disorder can exacerbate social and medical harms, including overdose risk. The study evaluated rates of amphetamine-type stimulant use among patients with untreated opioid use disorder presenting at emergency departments in Baltimore, MD; New York, NY; Cincinnati, OH; and Seattle, WA. METHODS: Emergency department (ED) patients with untreated opioid use disorder (N=396) and enrolled between February 2017 and January 2019 in a multisite hybrid type III implementation science study were evaluated for concurrent amphetamine-type stimulant use. Individuals with urine tests positive for methamphetamine, amphetamine, or both were compared with amphetamine-type stimulant-negative patients. RESULTS: Overall, 38% of patients (150/396) were amphetamine-type stimulant positive; none reported receiving prescribed amphetamine or methamphetamine medications. Amphetamine-type stimulant-positive versus -negative patients were younger: mean age was 36 years (SD 10 years) versus 40 years (SD 12 years), 69% (104/150) versus 46% (114/246) were white, 65% (98/150) versus 54% (132/246) were unemployed, 67% (101/150) versus 49 (121/246) had unstable housing, 47% (71/150) versus 25% (61/245) reported an incarceration during 1 year before study admission, 60% (77/128) versus 45% (87/195) were hepatitis C positive, 79% (118/150) versus 47% (115/245) reported drug injection during 1 month before the study admission, and 42% (62/149) versus 29% (70/244) presented to the ED for an injury. Lower proportions of amphetamine-type stimulant-positive patients had cocaine-positive urine test results (33% [50/150] versus 52% [129/246]) and reported seeking treatment for substance use problems as a reason for their ED visit (10% [14/148] versus 19% [46/246]). All comparisons were statistically significant at P<.05 with the false discovery rate correction. CONCLUSION: Amphetamine-type stimulant use among ED patients with untreated opioid use disorder was associated with distinct sociodemographic, social, and health factors. Improved ED-based screening, intervention, and referral protocols for patients with opioid use disorder and amphetamine-type stimulant use are needed.


Asunto(s)
Anfetamina/efectos adversos , Estimulantes del Sistema Nervioso Central/efectos adversos , Metanfetamina/efectos adversos , Trastornos Relacionados con Opioides/diagnóstico , Adulto , Anfetamina/uso terapéutico , Anfetamina/orina , Trastornos Relacionados con Anfetaminas/diagnóstico , Trastornos Relacionados con Anfetaminas/epidemiología , Estudios de Casos y Controles , Estimulantes del Sistema Nervioso Central/uso terapéutico , Estimulantes del Sistema Nervioso Central/orina , Sobredosis de Droga/etiología , Servicio de Urgencia en Hospital/estadística & datos numéricos , Femenino , Hepatitis C/epidemiología , Humanos , Masculino , Metanfetamina/uso terapéutico , Metanfetamina/orina , Persona de Mediana Edad , Trastornos Relacionados con Opioides/complicaciones , Trastornos Relacionados con Opioides/epidemiología , Trastornos Relacionados con Opioides/orina , Detección de Abuso de Sustancias , Estados Unidos/epidemiología
13.
Nephrology (Carlton) ; 25(10): 758-764, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32725693

RESUMEN

AIM: The effects of methamphetamine intoxication on the kidney are not well reported. We aimed to investigate acute kidney injury (AKI) associated with methamphetamine intoxication, in particular its severity, duration and association with rhabdomyolysis. METHODS: This is a prospective observational series of methamphetamine-intoxicated patients presenting to an Emergency Department. Patients self-reporting recent methamphetamine use, with a positive urine drug screen and an elevated creatinine, were eligible for the study. Urinary neutrophil gelatinase-associated lipocalin (NGAL) was measured, and serum creatinine, creatine kinase and cystatin C concentrations were performed on arrival and at several time points until discharge from hospital. Demographic and clinical data were obtained from the medical records. RESULTS: There were 634 presentations with methamphetamine intoxication over a 10-month period, with 73/595(12%) cases having an elevated serum creatinine concentration on arrival. Fifty presentations in 48 patients were included in the study. Most patients (85%) were male with a median age of 32 years. The median serum creatinine concentration on presentation was 125 µmol/L (IQR:113-135 µmol/L) with 45 (90%) presentations meeting diagnostic criteria for AKI. Concurrent rhabdomyolysis occurred in 22 (44%) presentations with a median CK of 2695 U/L (IQR:1598-5060 U/L). Cystatin C was elevated (> 0.98 mg/L) in 18 cases. An elevated NGAL concentration (>150 µg/L) was present in five (10%) cases. No patients required dialysis. The median length of stay was 19 hours (IQR 14-24 hours). CONCLUSION: AKI is common in methamphetamine intoxication. The kidney injury is relatively mild and short-lived, resolving with crystalloid therapy.


Asunto(s)
Lesión Renal Aguda , Biomarcadores/análisis , Soluciones Cristaloides/administración & dosificación , Lipocalina 2/orina , Metanfetamina/toxicidad , Rabdomiólisis , Lesión Renal Aguda/sangre , Lesión Renal Aguda/inducido químicamente , Lesión Renal Aguda/terapia , Lesión Renal Aguda/orina , Adulto , Australia/epidemiología , Estimulantes del Sistema Nervioso Central/toxicidad , Estimulantes del Sistema Nervioso Central/orina , Creatina Quinasa/sangre , Creatinina/sangre , Cistatina C/sangre , Femenino , Humanos , Riñón/efectos de los fármacos , Riñón/fisiopatología , Masculino , Metanfetamina/orina , Evaluación de Procesos y Resultados en Atención de Salud , Rabdomiólisis/inducido químicamente , Rabdomiólisis/diagnóstico , Índice de Severidad de la Enfermedad , Detección de Abuso de Sustancias/métodos
14.
Ther Drug Monit ; 42(5): 787-794, 2020 10.
Artículo en Inglés | MEDLINE | ID: mdl-32142018

RESUMEN

BACKGROUND: Neonatal abstinence syndrome is an array of signs and symptoms experienced by a newborn due to abrupt discontinuation of intrauterine exposure to certain drugs, primarily opioids. In the United States, the incidence of neonatal abstinence syndrome has tripled over the past decade. The current standard of care for drug testing includes the analysis of infant urine and meconium. Sample collection is associated with several limitations, including diaper media interferences, limited sample amount, sample heterogeneity, and the need for professional staff for collection. Umbilical cord tissue has emerged as a convenient sample matrix for testing owing to its universal availability. The purpose of this study was to examine umbilical cords using an untargeted metabolomics approach to determine the detected drugs and validate an analytical method to confirm and quantify the identified drugs. METHODS: A metabolomics analysis was performed with 21 umbilical cords to screen for drugs and drug metabolites by liquid chromatography-mass spectrometry. Drugs were identified using the National Institute of Standards and Technology database, and an analytical method was developed and validated using secondary liquid chromatography-mass spectrometry instrument for positive confirmation and quantitative analysis. RESULTS: Twenty-one random umbilical cords from women were tested: 4 were positive for cocaine and the primary and secondary metabolites; one was positive for methadone, the primary metabolite; 3 were positive for cotinine, the metabolite of nicotine; and 5 were positive for acetyl norfentanyl. CONCLUSIONS: Our research is a prospective method development study using untargeted and targeted approaches to characterize steady-state drug metabolite levels in the umbilical cord matrix at the time of delivery. By characterizing drug type and concentration, this methodology can be used to develop a reliable complementary testing method for meconium toxicology screens.


Asunto(s)
Analgésicos Opioides/metabolismo , Analgésicos Opioides/orina , Cordón Umbilical/metabolismo , Estimulantes del Sistema Nervioso Central/metabolismo , Estimulantes del Sistema Nervioso Central/orina , Cromatografía Liquida/métodos , Cocaína/metabolismo , Cocaína/orina , Femenino , Humanos , Meconio/metabolismo , Metabolómica/métodos , Metadona/metabolismo , Metadona/orina , Síndrome de Abstinencia Neonatal/metabolismo , Síndrome de Abstinencia Neonatal/orina , Embarazo , Estudios Prospectivos , Detección de Abuso de Sustancias/métodos , Espectrometría de Masas en Tándem/métodos
15.
Spectrochim Acta A Mol Biomol Spectrosc ; 231: 118077, 2020 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-32007904

RESUMEN

Methamphetamine (MA), a psychoactive substance with many medicinal applications in different countries, has destructive impacts on the nervous system and brain and can lead to addiction. The optimal system for MA determination must be able to measure the tiny amount of MA in complex matrixes accurately. In the current work, a simple and biocompatible sensitive optical probe was developed based on molecularly imprinted polymers (MIPs) technique and by using green CQDs and mesoporous structured imprinting microspheres (SiO2@CQDs@ms-MIPs). CQDs (ФF = 33%) were synthesized via the hydrothermal method using natural chewing gum as carbon source. SiO2 nanoparticles were used as the backup substrate for the placement of CQDs. In spite of biocompatibility, porosity and having high specific area are the unique features of SiO2 nanoparticles. When MA is present, the fluorescence response of MIPs enhances. This is caused by the passivation and adjustment of active clusters that are present on the surface of CQDs. By this optical sensor, the favorable linear dynamic range (5.0-250 µM) and the detection limit (1.6 µM) were obtained. The applicability of the advanced sensor was studied in real samples such as human urine and human blood plasma. Acceptable results were obtained and recovery amounts were in the 92-110% interval.


Asunto(s)
Estimulantes del Sistema Nervioso Central/sangre , Estimulantes del Sistema Nervioso Central/orina , Metanfetamina/sangre , Metanfetamina/orina , Impresión Molecular , Nanopartículas/química , Carbono/química , Monitoreo de Drogas , Tecnología Química Verde , Humanos , Límite de Detección , Impresión Molecular/métodos , Transición de Fase , Porosidad , Puntos Cuánticos/química , Dióxido de Silicio/química , Espectrometría de Fluorescencia/métodos
16.
Drug Test Anal ; 12(6): 785-797, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-31950617

RESUMEN

The constant legal adaptation of new psychoactive substances (NPS), challenges their evaluation in different fields. In sports, NPS are prohibited in competition with a reporting limit (RL) of 50 ng/mL for the parent compound or a metabolite. However, there is a lack of comprehensive methodologies and excretion studies for monitoring NPS. This work aims to develop an analytical methodology for the NPS quantification and to evaluate the suitability of monitoring the urinary parent stimulants after NPS misuse. A method for the quantification of 14 common NPS was developed and validated. The method was found to be linear in the range 1-1000 ng/mL, and was shown to be accurate and precise. A lowest limit of quantification (LLOQ) of 1 ng/mL was established for all analytes except for benzylpiperazine (5 ng/mL). The method was able to confirm the identity of the analytes at the LLOQ for most NPS. The methodology was applied to the quantification of the parent compound in urine samples collected from an observational study where several healthy volunteers (n ≥ 6 per drug) ingested active doses of mephedrone (MEPH), methylone (MDMC), 2,5-dimetoxy-4-ethylphenetylamine (2C-E), or 6-(2-aminopropyl)benzofuran (6-APB). It was observed that for MDMC and 6-APB, the quantification of the urinary parent drug at the current RL is a proper strategy for detecting their misuse. However, this strategy seems to be insufficient for evaluating MEPH and 2C-E misuse. Monitoring the most abundant metabolite of MEPH (4'-carboxy-MEPH) and the reduction of the RL to 10 ng/mL for the 2C-E evaluation are proposed.


Asunto(s)
Estimulantes del Sistema Nervioso Central/orina , Doping en los Deportes/métodos , Psicotrópicos/orina , Detección de Abuso de Sustancias/métodos , Adulto , Cromatografía Líquida de Alta Presión , Femenino , Humanos , Drogas Ilícitas , Límite de Detección , Masculino , Espectrometría de Masas , Metanfetamina/análogos & derivados , Metanfetamina/orina , Estudios Prospectivos , Estándares de Referencia , Reproducibilidad de los Resultados
17.
Forensic Sci Med Pathol ; 15(4): 598-602, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31444700

RESUMEN

In this report, a pediatric case of bowel obstruction with sepsis complicated by methamphetamine toxicity is described. The decedent, an eleven-year-old female with a clinical history of pica, was found unresponsive in her home and pronounced dead following unsuccessful resuscitative efforts. Radiologic imaging showed multiple radio-opaque foreign objects in the stomach and bowel. Autopsy revealed a green leafy substance, coins and other metallic items, folded paper, and plastic in her stomach and bowels. Postmortem iliac blood and urine tested positive for amphetamine and methamphetamine. While the decedent's medical history and autopsy findings provided evidence consistent with bowel obstruction with sepsis due to the ingestion of foreign materials, the high methamphetamine concentration was suggestive of concurrent methamphetamine toxicity. Unique complications associated with this case include the phenomenon that methamphetamine toxicity and bowel obstruction can present similarly in children and the reported opinion that accidental drug ingestion is uncommon in children over the age of five. This case emphasizes that the age range for suspected accidental drug ingestion should be expanded for those with pica, as these patients, despite being older, may not be able to differentiate between what they should and should not ingest. Furthermore, when treating a pediatric patient with pica that appears to present with bowel obstruction, unintentional drug ingestion should also be considered, particularly if there is a suspicion that the child lives in a household where drugs are abused, given the prospect that drug toxicity can present similarly.


Asunto(s)
Estimulantes del Sistema Nervioso Central/efectos adversos , Obstrucción Intestinal/etiología , Metanfetamina/efectos adversos , Pica/complicaciones , Sepsis/etiología , Anfetamina/sangre , Anfetamina/orina , Estimulantes del Sistema Nervioso Central/sangre , Estimulantes del Sistema Nervioso Central/orina , Niño , Colon Sigmoide/diagnóstico por imagen , Sobredosis de Droga , Femenino , Cuerpos Extraños/diagnóstico por imagen , Humanos , Obstrucción Intestinal/diagnóstico por imagen , Metanfetamina/sangre , Metanfetamina/orina , Sepsis/patología , Estómago/diagnóstico por imagen
18.
J Burn Care Res ; 40(6): 734-742, 2019 10 16.
Artículo en Inglés | MEDLINE | ID: mdl-31309978

RESUMEN

Previous research on burn patients who test positive for methamphetamines (meth) has yielded mixed results regarding whether meth-positive status leads to worse outcomes and longer hospitalizations. We hypothesized that meth-positive patients at our regional burn center would have worse outcomes. We reviewed burn admissions from January 2014 to December 2017 and compared total patients versus meth-positive, and matched meth-negative versus meth-positive for total BSA burn, length of stay (LOS), intensive care unit (ICU) days, days on ventilator, discharge status (lived/died), number of operating room (OR) visits, number of procedures, socioeconomic status, comorbidities, and discharge disposition. Of 1363 total patients, 264 (19.4%) were meth-positive on toxicology screen. We matched 193 meth-positive patients with meth-negative controls based on TBSA burn, age, and inhalation injury. In the total population comparison, meth-positive patients had larger burns (15.6% vs 12.2%; P = .004), longer LOS (17.8 vs 14.3 days; P = .041), and fewer operations/TBSA (0.12 vs 0.2; P = .04), and lower socioeconomic status. Meth-positive patients were less likely to be discharged to a skilled nursing facility, and more likely to leave against medical advice. In the matched patients, we found no significant differences in LOS or OR visits/TBSA burn. Meth-positive patients have lower socioeconomic status, larger burns, and longer LOS compared to the total burn population. Methamphetamine use, by itself, does not appear to change outcomes. Methamphetamine use leads to larger burns in a population with fewer resources than the general population.


Asunto(s)
Quemaduras/epidemiología , Estimulantes del Sistema Nervioso Central/orina , Escolaridad , Tiempo de Internación/estadística & datos numéricos , Metanfetamina/orina , Pobreza , Adulto , Trastornos Relacionados con Anfetaminas/complicaciones , Quemaduras/cirugía , Estudios de Casos y Controles , Tráfico de Drogas , Hospitalización , Humanos , Unidades de Cuidados Intensivos , Alta del Paciente , Pacientes Desistentes del Tratamiento/estadística & datos numéricos , Prisiones , Respiración Artificial/estadística & datos numéricos , Estudios Retrospectivos , Clase Social , Procedimientos Quirúrgicos Operativos/estadística & datos numéricos , Índices de Gravedad del Trauma , Estados Unidos/epidemiología
20.
Artículo en Inglés | MEDLINE | ID: mdl-31310949

RESUMEN

A nano graphene oxide sol-gel composite (NGO/sol-gel) applied as a coating of a capillary glass tube stir bar to develop a novel stir bar sorptive extraction (SBSE) method for simultaneous extraction of amphetamine (AMP) and methamphetamine (MET) from biological urine sample. Lab-synthesized NGO was applied with methyltrimethoxysilane (MTMOS) and Tetraethoxysilane (TEOS) as sol-gel precursor. NGO/sol-gel was deposited on the surface of a capillary glass tube to prepare stir bar sorptive extraction adsorbent by a simple and fast method. The scanning electron micrograph images showed a three dimensional structure of lab-made device suitable for SBSE method for simultaneous extraction of AMP and MET. Effective extraction parameters were investigated. Through studied suitable extraction conditions, satisfactory linearity was achieved in the concentration range of 50-2000 ngmL-1 for AMP and 40-2500 ngmL-1 for MET. The relative recovery of the analytes were 99.5 and 99.7% for AMP and MET, respectively for positive urine samples were studied by novel introduced method. The results cleared that NGO/sol-gel composite could be used as practical method in laboratories as an efficient SBSE adsorbent for drugs determination in urine matrix.


Asunto(s)
Estimulantes del Sistema Nervioso Central/aislamiento & purificación , Estimulantes del Sistema Nervioso Central/orina , Cromatografía Líquida de Alta Presión/métodos , Metanfetamina/aislamiento & purificación , Extracción en Fase Sólida/métodos , Adsorción , Anfetaminas/análisis , Anfetaminas/aislamiento & purificación , Carbono , Cromatografía Líquida de Alta Presión/instrumentación , Humanos , Límite de Detección , Metanfetamina/análisis , Nanopartículas/química , Extracción en Fase Sólida/instrumentación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA